AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23997361 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy (Thornton Adjustable Positioner type‐1, Airway Management, Inc., Dallas, TX, USA)
Number of subjects: 103
Study 23997361 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 103
Study 21050560 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 42
Study 21050560 — intervention group
Group type: COMPARATOR
Intervention: Band ligation
Number of subjects: 42
Study 18755566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictograph
Number of subjects: 2412
Study 18755566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tables
Number of subjects: 2412
Study 18755566 — intervention group
Group type: COMPARATOR
Intervention: All formats
Number of subjects: 2412
Study 18755566 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbatim and gist knowledge
Number of subjects: 2412
Study 15973829 — intervention group
Group type: EXPERIMENTAL
Intervention: 600‐grit ground plus silanation
Number of subjects: 24
Study 15973829 — intervention group
Group type: EXPERIMENTAL
Intervention: air‐particle abrasion plus silanation
Number of subjects: 24
Study 15973829 — intervention group
Group type: COMPARATOR
Intervention: 600‐grit ground only
Number of subjects: 24
Study 15973829 — intervention group
Group type: COMPARATOR
Intervention: 600‐grit ground plus air‐particle abrasion
Number of subjects: 24
Study 12935441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous liposomal all-trans-retinoic acid (L-ATRA) 90 mg/m² every other day for 15 days
Number of subjects: 29
Study 12935441 — intervention group
Group type: COMPARATOR
Intervention: Oral ATRA (Vesanoid) 45 mg/m² daily for 15 days
Number of subjects: 29
Study 12935441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous liposomal all-trans-retinoic acid (L-ATRA)
Number of subjects: 29
Study 12935441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous liposomal all-trans-retinoic acid (L-ATRA) and Oral ATRA
Number of subjects: 29
Study 10827385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary dipyridamole
Number of subjects: 491
Study 10827385 — intervention group
Group type: COMPARATOR
Intervention: Conventional pretreatment (heparin and aspirin)
Number of subjects: 491
Study 8702050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 62
Study 8702050 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 62
Study 1712433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 19
Study 1712433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 19
Study 1712433 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 19
Study 6851813 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiografin mixed with lidocaine
Number of subjects: 92
Study 6851813 — intervention group
Group type: COMPARATOR
Intervention: Hexabrix
Number of subjects: 92
Study 31958293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 42
Study 31958293 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-metronidazole
Number of subjects: 42
Study 31026384 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stabilization exercises
Number of subjects: 49
Study 29465097 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivators to physical activity
Number of subjects: 50
Study 29465097 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to physical activity
Number of subjects: 50
Study 29465097 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 50
Study 29465097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to increase walking
Number of subjects: 50
Study 27057878 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compressions with PPE
Number of subjects: 40
Study 27057878 — intervention group
Group type: COMPARATOR
Intervention: Chest compressions without PPE
Number of subjects: 40
Study 27057878 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological parameters with PPE
Number of subjects: 40
Study 25439136 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (200,000 I.U.) plus zinc sulfate
Number of subjects: 24
Study 25439136 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A (200,000 I.U.) plus placebo
Number of subjects: 24
Study 22739142 — intervention group
Group type: EXPERIMENTAL
Intervention: LX4211 150 mg
Number of subjects: 36
Study 22739142 — intervention group
Group type: EXPERIMENTAL
Intervention: LX4211 300 mg
Number of subjects: 36
Study 22739142 — intervention group
Group type: EXPERIMENTAL
Intervention: LX4211 300 mg (follow-up single-dose study)
Number of subjects: 36
Study 22739142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19664264 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity shoulder elevation
Number of subjects: 18
Study 16909876 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial cuing (automated aid)
Number of subjects: 0
Study 16909876 — intervention group
Group type: EXPERIMENTAL
Intervention: Text cuing (automated aid)
Number of subjects: 0
Study 16909876 — intervention group
Group type: COMPARATOR
Intervention: No assistance (Control group)
Number of subjects: 0
Study 12781596 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone (two doses)
Number of subjects: 116
Study 12781596 — intervention group
Group type: EXPERIMENTAL
Intervention: PIMS scores
Number of subjects: 116
Study 11187914 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment without asparaginase (ASP)
Number of subjects: 1191
Study 11187914 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS control without cranial irradiation
Number of subjects: 1191
Study 11187914 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour daunorubicin (DNR) infusion
Number of subjects: 1191
Study 11187914 — intervention group
Group type: EXPERIMENTAL
Intervention: DNR response
Number of subjects: 1191
Study 11187914 — intervention group
Group type: COMPARATOR
Intervention: Rapid rotation regimen
Number of subjects: 1191
Study 11187914 — intervention group
Group type: COMPARATOR
Intervention: 6-thioguanine (6-TG) in maintenance treatment
Number of subjects: 1191
Study 11187914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification of systemic treatment
Number of subjects: 1191
Study 8838763 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis (EA; 11 weeks to 12 weeks and 6 days)
Number of subjects: 683
Study 8838763 — intervention group
Group type: COMPARATOR
Intervention: Midtrimester amniocentesis (MA; 15 weeks to 16 weeks and 6 days)
Number of subjects: 683
Study 8838763 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis (EA)
Number of subjects: 683
Study 8838763 — intervention group
Group type: COMPARATOR
Intervention: Midtrimester amniocentesis (MA)
Number of subjects: 683
Study 1283570 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR 480 mg/day
Number of subjects: 0
Study 1283570 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR 240 mg/day
Number of subjects: 0
Study 1283570 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil IR (80 or 160 mg 3 times daily)
Number of subjects: 0
Study 1283570 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR and IR
Number of subjects: 0
Study 1283570 — intervention group
Group type: COMPARATOR
Intervention: Verapamil IR
Number of subjects: 0
Study 1283570 — intervention group
Group type: COMPARATOR
Intervention: Verapamil SR
Number of subjects: 0
Study 6431471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 0
Study 6431471 — intervention group
Group type: COMPARATOR
Intervention: Increasing arousal during material presentation
Number of subjects: 0
Study 31004517 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard tablet (ST‐OS)
Number of subjects: 21
Study 31004517 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension in solid lipid nanoparticles (SLN-OS)
Number of subjects: 21
Study 31004517 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal jellified melatonin microemulsion (μE-TD)
Number of subjects: 21
Study 28623849 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (3,4-DAP) free base
Number of subjects: 49
Study 27048477 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted Cascade Training and Supervision (TACTS)
Number of subjects: 80
Study 27048477 — intervention group
Group type: COMPARATOR
Intervention: Specialist-delivered training
Number of subjects: 80
Study 25112783 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantago ovata husk
Number of subjects: 18
Study 25112783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 25112783 — intervention group
Group type: COMPARATOR
Intervention: Initial situation
Number of subjects: 18
Study 25112783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber treatment (Plantago ovata husk)
Number of subjects: 18
Study 25112783 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study 22575433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial images and electronic drug monitoring (EDM) review used in counseling
Number of subjects: 204
Study 22575433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 204
Study 22575433 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling tools (pictorial images and EDM)
Number of subjects: 204
Study 19602273 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 414
Study 19602273 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 414
Study 19602273 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 414
Study 19602273 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (24 weeks)
Number of subjects: 414
Study 17470863 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise therapy
Number of subjects: 108
Study 17470863 — intervention group
Group type: COMPARATOR
Intervention: Exercise-placebo (body conditioning)
Number of subjects: 108
Study 17470863 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study 16921051 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation (AD) for 7 months followed by continuous AD
Number of subjects: 1345
Study 16921051 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation (AD) for 7 months followed by intermittent AD
Number of subjects: 1345
Study 16921051 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation (AD) for 7 months
Number of subjects: 1345
Study 12972790 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder/recall
Number of subjects: 1203
Study 12972790 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up
Number of subjects: 1203
Study 11059179 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy elderly subjects (above the age of 60 years)
Number of subjects: 60
Study 11059179 — intervention group
Group type: COMPARATOR
Intervention: Young volunteers
Number of subjects: 60
Study 8849215 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg once daily for 3 days)
Number of subjects: 154
Study 8849215 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (50,000 U/kg/day in two divided doses for 10 days)
Number of subjects: 154
Study 1627425 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural-network-based artificial intelligence for treatment decision-making
Number of subjects: 9000
Study 1627425 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural-network technique
Number of subjects: 9000
Study 6744791 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training for 36 weeks
Number of subjects: 6
Study 29903720 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (UCM)
Number of subjects: 73
Study 29903720 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 73
Study 29317418 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine group
Number of subjects: 55
Study 29317418 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 55
Study 27748575 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine oral care with tongue cleaning (intervention group; n = 58)
Number of subjects: 114
Study 27748575 — intervention group
Group type: COMPARATOR
Intervention: Routine oral care alone (control group; n = 56)
Number of subjects: 114
Study 24708472 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived MSCs (1 × 10^6 cells/kg of body weight)
Number of subjects: 12
Study 24708472 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study 22048283 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Passiflora incarnata Linneaus extract
Number of subjects: 60
Study 22048283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20084463 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity at an intensity >3 METs
Number of subjects: 183
Study 18096343 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (20mg, 2ml, Hyalgan)
Number of subjects: 56
Study 18096343 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (control group)
Number of subjects: 56
Study 16003527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole alone or in combination with L-dopa
Number of subjects: 453
Study 16003527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 453
Study 11826422 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (2 x 100 mg p.o. QD) with interferon alfa-2a (6 MIU sc thrice weekly for 20 weeks, then 3 MIU sc thrice weekly)
Number of subjects: 246
Study 11826422 — intervention group
Group type: COMPARATOR
Intervention: Placebo with interferon alfa-2a (6 MIU sc thrice weekly for 20 weeks, then 3 MIU sc thrice weekly)
Number of subjects: 246
Study 11826422 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (2 x 100 mg p.o. QD) with interferon alfa-2a
Number of subjects: 246
Study 11826422 — intervention group
Group type: COMPARATOR
Intervention: Placebo with interferon alfa-2a
Number of subjects: 246
Study 11826422 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine therapy
Number of subjects: 246
Study 11826422 — intervention group
Group type: COMPARATOR
Intervention: Amantadine and placebo
Number of subjects: 246
Study 10397536 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate (20 mg pentavalent antimony per kg per day for 28 days)
Number of subjects: 89
Study 10397536 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (0.7 mg/kg per day for 28 days)
Number of subjects: 89
Study 7740021 — intervention group
Group type: EXPERIMENTAL
Intervention: fitness
Number of subjects: 1147
Study 7740021 — intervention group
Group type: EXPERIMENTAL
Intervention: fitness + school nutrition
Number of subjects: 1147
Study 7740021 — intervention group
Group type: EXPERIMENTAL
Intervention: school-based nutrition
Number of subjects: 1147
Study 7740021 — intervention group
Group type: EXPERIMENTAL
Intervention: school + home nutrition
Number of subjects: 1147
Study 7740021 — intervention group
Group type: EXPERIMENTAL
Intervention: home-based nutrition
Number of subjects: 1147
Study 7740021 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 1147
Study 2202954 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 300
Study 2202954 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 300
Study 2202954 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 300
Study 6993035 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy with levamisole (2.5 mg/kg orally for 2 consecutive days each week while off chemotherapy)
Number of subjects: 77
Study 6993035 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (standard regimen of cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 77
Study 6993035 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy with levamisole
Number of subjects: 77
Study 6993035 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 77
Study 31430414 — intervention group
Group type: EXPERIMENTAL
Intervention: LINK (buprenorphine induction, in-patient dose stabilization and post-discharge transition to maintenance buprenorphine)
Number of subjects: 115
Study 31430414 — intervention group
Group type: COMPARATOR
Intervention: WM (5-day buprenorphine managed withdrawal protocol)
Number of subjects: 115
Study 29458934 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy with lavender oil for 5 sessions over 3 cycles
Number of subjects: 77
Study 29458934 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aromatherapy)
Number of subjects: 77
Study 28322468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated dietitian (DD)
Number of subjects: 178
Study 28322468 — intervention group
Group type: COMPARATOR
Intervention: Trained hospital dietitian (THD)
Number of subjects: 178
Study 28322468 — intervention group
Group type: COMPARATOR
Intervention: Existing practice (EP)
Number of subjects: 178
Study 26261640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenosides (GS) + Ulinastatin (UTI)
Number of subjects: 80
Study 26261640 — intervention group
Group type: COMPARATOR
Intervention: Ulinastatin (UTI)
Number of subjects: 80
Study 24061340 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 272
Study 24061340 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 272
Study 21436337 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization Transfer Imaging (MTI)
Number of subjects: 20
Study 21436337 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 18251615 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (American Orthodontics, AISI 316L)
Number of subjects: 30
Study 18251615 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (Dentaurum, AISI 316L)
Number of subjects: 30
Study 18251615 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (3M/Unitek, AISI 303)
Number of subjects: 30
Study 18251615 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 30
Study 16646673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) plus G-CSF
Number of subjects: 29
Study 16646673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) plus GM-CSF
Number of subjects: 29
Study 16646673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) plus GM-CSF followed by G-CSF
Number of subjects: 29
Study 16646673 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF-containing regimen
Number of subjects: 29
Study 12692927 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health nursing visit awareness
Number of subjects: 10749
Study 12692927 — intervention group
Group type: EXPERIMENTAL
Intervention: Visiting nursing agencies' service awareness
Number of subjects: 10749
Study 12692927 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire to use public health nursing visit service
Number of subjects: 10749
Study 12692927 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire to use visiting nursing agencies' service
Number of subjects: 10749
Study 10962675 — intervention group
Group type: EXPERIMENTAL
Intervention: Full strength Burow's solution (13% aluminium acetate)
Number of subjects: 67
Study 10962675 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.25% aluminium acetate solution (a quarter strength Burow's solution)
Number of subjects: 67
Study 10962675 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3% aluminium acetate solution (1/10 strength Burow's solution)
Number of subjects: 67
Study 8890945 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 233
Study 8890945 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lung cancer (squamous cell carcinoma)
Number of subjects: 233
Study 1643680 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 66
Study 1643680 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 66
Study 6230195 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 13
Study 6230195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30277807 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme (six session intervention programme including phrasing of individual action plans and group discussions)
Number of subjects: 118
Study 30277807 — intervention group
Group type: COMPARATOR
Intervention: Standard care (received by both intervention and control groups)
Number of subjects: 118
Study 29138916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral retinaculum plasty and MPFL reconstruction
Number of subjects: 59
Study 29138916 — intervention group
Group type: COMPARATOR
Intervention: Lateral retinacular release and MPFL reconstruction
Number of subjects: 59
Study 27298569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (MG)
Number of subjects: 60
Study 27298569 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (PG)
Number of subjects: 60
Study 27298569 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CG)
Number of subjects: 60
Study 25330631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 2 years followed by 1 year follow-up and combined with 3-year drug therapy
Number of subjects: 120
Study 25330631 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only drug therapy
Number of subjects: 120
Study 24111623 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-step proactive coping intervention targeting proactive coping skills
Number of subjects: 141
Study 24111623 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster phase of the intervention
Number of subjects: 141
Study 24111623 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical variables assessed at T1 and T4
Number of subjects: 141
Study 20138095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 15
Study 20138095 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine
Number of subjects: 15